Research Alliance Corporation IV prices $75M IPO on Nasdaq Jul 13, 2026 09:05AM
Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial Jul 13, 2026 06:00AM
Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P. Jul 7, 2026 04:42PM
Vor Bio names David Zaccardelli to its board of directors Jul 7, 2026 04:01PM
Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. Jul 2, 2026 08:27PM
View Older Stories

Jun 29, 2026 07:02AM Talawar Therapeutics to go public via SPAC deal with $225M PIPE
Jun 26, 2026 05:39PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 24, 2026 08:00PM Ollin Biosciences raises $330M Series B to fund eye disease trials
Jun 24, 2026 06:49PM Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 24, 2026 07:01AM Ollin Biosciences raises $330M Series B for eye disease drug trials
Jun 23, 2026 07:30AM Boundless Bio agrees to merge with Serapha Bio in all-stock deal
Jun 22, 2026 07:02PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 18, 2026 04:10PM Form SCHEDULE 13D Parabilis Medicines, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 15, 2026 08:16PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 15, 2026 07:37PM Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 4, 2026 05:01PM Form SCHEDULE 13G Q32 Bio Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Jun 3, 2026 04:46PM Form SCHEDULE 13G Editas Medicine, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 27, 2026 08:41AM Q32 Bio shares up 26% on $55 million financing round
May 27, 2026 08:00AM Q32 Bio raises $55 million in private placement financing
May 21, 2026 09:13PM Form SCHEDULE 13G Sana Biotechnology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 20, 2026 09:00AM Research Alliance Corporation III prices $75 million IPO at $10 per share
May 15, 2026 04:51PM Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:49PM Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:47PM Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:47PM Form SCHEDULE 13G/A Invivyd, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:46PM Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:44PM Form SCHEDULE 13G/A Contineum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:43PM Form SCHEDULE 13G/A Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:42PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:41PM Form SCHEDULE 13G Atrium Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:36PM Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
May 15, 2026 04:34PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
May 15, 2026 09:00AM Sana Biotechnology raises $69 million through share sale
May 14, 2026 05:24PM Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 13, 2026 05:48PM Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 11, 2026 05:46PM Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
May 8, 2026 06:52AM Artiva Biotherapeutics prices $300 million stock and warrant offering
May 1, 2026 04:11PM Form SCHEDULE 13G Altimmune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 29, 2026 06:44PM Form SCHEDULE 13D/A Climb Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 28, 2026 05:16PM Form SCHEDULE 13G Prelude Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 28, 2026 07:00AM Climb Bio raises $110 million in private placement
Apr 27, 2026 04:46PM Form SCHEDULE 13G JATT II Acquisition Corp Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 27, 2026 07:00AM Altimmune closes $225 million public offering for liver drug development
Apr 23, 2026 06:56PM Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 21, 2026 07:06PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 20, 2026 06:31AM Prelude Therapeutics prices $90 million stock offering at $4.44 per share
Apr 17, 2026 04:57PM Form SCHEDULE 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 17, 2026 08:00AM Tyra Biosciences appoints Habib Dable to board of directors
Apr 15, 2026 05:31PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 14, 2026 02:08PM Galera and Obsidian merge in $350 million all-stock deal
Apr 14, 2026 08:54AM Obsidian Therapeutics and Galera Therapeutics announce merger with $350M funding
Apr 13, 2026 05:23PM Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 10, 2026 06:25PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 8, 2026 06:45PM Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 7, 2026 06:00PM Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
View Older Stories